Back to Research Home
USNAUSANA Health Sciences Inc
Health Care · Medicinal Chemicals and Botanical Products · Micro
$13.96−3.86%
As of 23 Oct 2026Mkt cap $269M
Stage 13
AVOID
Fundamentals
31.7/75
Technical
4.7/15
Independent
36.4/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −2.1%
- 3M
- −37.5%
- 6M
- −28.2%
- 1Y
- −33.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —Hist median 15.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 16.3x
- FCF yield
- 6.1%
Quality
- ROIC
- —
- Operating margin
- 7.8%
- FCF margin
- 0.9%
- Current ratio
- 2.2x
Growth
- Revenue growth
- +8.3%Latest FY YoY
- Revenue CAGR
- −6.0%
- EPS CAGR
- −43.6%
- FCF CAGR
- −47.0%
Capital
- Share-count trend
- −2.0%3Y annualised
- Net cash
- $140M-6.3x OCF
Annual trend
- CAGR 2021–2025
- −6.0%
- Latest · 2025
- $1B
- YoY
- +8.3%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-03
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded